Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05667493 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

StatusEnrolling by Invitation
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 122 to 134v12
  2. Re-verified, no change to tracked fieldsv11
  3. Study sites: 98 to 122v10
  4. Primary endpoints: 9 to 4 Trial status: Recruiting to Enrolling by Invitation · Primary completion date: Apr 2029 to Aug 2029 · Secondary endpoints: 7 to 3 · 2 morev9 Show 5 more changesShow less
    • Trial status: Recruiting to Enrolling by Invitation
    • Primary completion date: Apr 2029 to Aug 2029
    • Secondary endpoints: 7 to 3
    • Study description shortened, about 26 words
    • Site details revised at 98 of 98 sites

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 59 to 98v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 32 to 59v7
  2. Study sites: 25 to 32v6
  3. Study sites: 3 to 25v5
  4. Study sites: 2 to 3v4
  5. Study sites: 1 to 2v3
  6. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
Trial Details
NCT Number NCT05667493
Lead Sponsor Ionis Pharmaceuticals, Inc.
Collaborators: AstraZeneca
Conditions Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Enrollment 1,400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov